NEW YORK, Nov. 29, 2011 /PRNewswire/ -- Senesco
Technologies, Inc. (NYSE AMEX: SNT) announced that that
Leslie J. Browne, Ph.D., President
and CEO, will present at RetailInvestorConferences.com.
DATE: December 1, 2011
TIME: 10:00 AM EST
LINK: www.retailinvestorconferences.com > Click the red
"register/ watch event now" button.
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time both in the
presentation hall as well as the company's "virtual trade booth."
If attendees are not able to join the event live in real-time, an
on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and
receive event updates.
Senesco recently initiated patient dosing at the Mayo Clinic in
Rochester, MN, in a Phase 1b/2a
clinical study of SNS01-T, the Company's lead therapeutic candidate
for the treatment of multiple myeloma, and also indicated its plan
to initiate in 2012 an additional clinical study of SNS01-T in
other B-cell cancers. The Company has demonstrated in the
laboratory that SNS01-T can significantly inhibit the growth of
both human mantle cell and diffuse large B-cell lymphomas in a dose
dependent manner in mouse xenograft models. Potential additional
effectiveness was observed from in vitro studies in which SNS01-T
was combined with other approved myeloma drugs. "We believe we have
shown that certain myeloma drugs can be up to 40 times more potent
in vitro when used in combination with SNS01-T," stated
Leslie J. Browne, Ph.D., President
and CEO of Senesco. "Together these results further reinforce the
significance of our target, eIF5A, and will guide us in designing
our future clinical studies."
About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type
of white blood cell derived from B-lymphocytes, normally
responsible for the production of antibodies. Malignant plasma
cells accumulate in the bone marrow leading to bone lesions and
interfering with the production of normal white blood cells. Median
survival time from first treatment is 2½ to 5 years depending on
disease stage at diagnosis. In the United
States there are approximately 20,000 newly diagnosed cases
of multiple myeloma annually and a total of approximately 65,000
patients with the disease. Senesco was previously granted orphan
drug status for SNS01-T, the Company's lead drug candidate for
treatment of multiple myeloma.
About Senesco Technologies, Inc.
Senesco Technologies is leveraging proprietary technology that
regulates programmed cell death, or apoptosis. Accelerating
apoptosis may have applications in treating cancer, while delaying
apoptosis may have applications treating certain inflammatory and
ischemic diseases. The Company has initiated a clinical study in
multiple myeloma with its lead therapeutic candidate SNS01-T.
Senesco has already partnered with leading-edge companies engaged
in agricultural biotechnology, and is entitled to earn research and
development milestones and royalties if its gene-regulating
platform technology is incorporated into its partners'
products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company's gene technology; the approval of the
Company's patent applications; the successful implementation of the
Company's research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company's products; the timing and success of the
Company's preliminary studies, preclinical research and clinical
trials; competition and the timing of projects and trends in future
operating performance, the Company's ability to comply with the
continued listing standards of the NYSE Amex, as well as other
factors expressed from time to time in the Company's periodic
filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with the
Company's periodic filings with the SEC. The forward-looking
statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
About RetailInvestorConferences.com:
RetailInvestorConferences.com, created by BetterInvesting
(NAIC), PR Newswire and MUNCmedia, is the first monthly
virtual investor conference series that provides an interactive
forum for presenting companies to meet directly with retail
investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based
investor conferences, Retail Investor Conferences unites PR
Newswire's leading-edge online conferencing and investor
communications capabilities with BetterInvesting's extensive retail
investor audience network and MUNCmedia's sophisticated retail
investor targeting.
SOURCE Senesco Technologies, Inc.